Lei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lei Li has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Aiwei Feng
Department of Interventional Radiology, Peking University Cancer Hospital, Beijing, China
1 shared publication- Akira Nishiyama
Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
1 shared publication - Apichat Kaewdech
Prince of Songkla University
1 shared publication - Arndt Vogel
Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada
1 shared publication - Bin Wu
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
1 shared publication Bincheng Ren
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
1 shared publication
Latest Publications
- Open Access
- 12 September 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (1) , 101216
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
- 12 September 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (1) , 101216
Open AccessTumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
- 22 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 167-172
BERT and Word Segmentation Algorithm Research on the Relationship Between Diabetes Symptoms and Traditional Chinese Medicine
Diabetes is a common chronic Metabolic disorder, and its treatment has always been a hot research topic in the medical field. Traditional Chinese medicine has a significant therapeutic effect on it and has become one of the important ways for patients to choose treatment methods. In recent years, with the development and application of deep learning technology, more and more research has begun to attempt to use deep learning models to process traditional Chinese medicine case data, achieving automated information extraction and analysis. This study shows that BERT model and jieba segmentation algorithm have good effect in the study of the relationship between symptoms and Medication in diabetes medical record data, which is expected to provide scientific basis and reference for clinical treatment of traditional Chinese medicine.
- 22 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 167-172
BERT and Word Segmentation Algorithm Research on the Relationship Between Diabetes Symptoms and Traditional Chinese Medicine
Diabetes is a common chronic Metabolic disorder, and its treatment has always been a hot research topic in the medical field. Traditional Chinese medicine has a significant therapeutic effect on it and has become one of the important ways for patients to choose treatment methods. In recent years, with the development and application of deep learning technology, more and more research has begun to attempt to use deep learning models to process traditional Chinese medicine case data, achieving automated information extraction and analysis. This study shows that BERT model and jieba segmentation algorithm have good effect in the study of the relationship between symptoms and Medication in diabetes medical record data, which is expected to provide scientific basis and reference for clinical treatment of traditional Chinese medicine.
- 1 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 56, 128464
Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH
- 1 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 56, 128464
Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH
- 1 July 2021
- Published by Elsevier in Gastroenterology
- Vol. 161 (1) , 370-371
Letter to the Editor: Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: A Meta-analysis of Individual Patient Data
- 1 July 2021
- Published by Elsevier in Gastroenterology
- Vol. 161 (1) , 370-371
Letter to the Editor: Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: A Meta-analysis of Individual Patient Data
- 1 August 2020
- Vol. 45 (16) , 3784-3789
[Research progress of traditional Chinese medicine in regulating autophagy and ischemic heart disease].
Ischemic heart disease(IHD) is a common and frequently-occurring disease that causes serious harm to human health. Autophagy is a life process that maintains cell homeostasis by degrading macromolecules such as damaged organelles in cells. In the process of ischemic heart disease development, on the one hand, cardiomyocytes degrade macromolecules such as damaged organelles by autophagy to provide material basis for energy synthesis and maintain cell homeostasis; on the other hand, over-activated autophagy can also increase cardiomyocyte death. Ischemic heart disease has a complex pathological mechanism, and the occurrence of autophagy is closely related to the survival or death of myocardial cells, so the regulation of autophagy may be an important therapeutic target for ischemic heart disease. Traditional Chinese medicine(TCM) with obvious effects, unique advantages and great potential has been widely used in the treatment of ischemic heart disease. In recent years, more and more studies have found that TCM can protect myocardium by regulating autophagy of cardiomyocytes. In this review, we summarized recent studies on the regulation of autophagy in myocardial cells by traditional Chinese medicine in ischemic heart disease. The pharmacological mechanism of Chinese medicinein regulating autophagy to protect cardiomyocytes was reviewed through different ways(promoting or inhibiting autophagy) from three levels, i.e. active ingredient, as well as drug pair and compound. The specific mechanism of Chinese medicine in regulating autophagy to protect ischemic heart disease was explored to provide references or new ideas for clinical treatment and drug development of ischemic heart disease.
- 1 August 2020
- Vol. 45 (16) , 3784-3789
[Research progress of traditional Chinese medicine in regulating autophagy and ischemic heart disease].
Ischemic heart disease(IHD) is a common and frequently-occurring disease that causes serious harm to human health. Autophagy is a life process that maintains cell homeostasis by degrading macromolecules such as damaged organelles in cells. In the process of ischemic heart disease development, on the one hand, cardiomyocytes degrade macromolecules such as damaged organelles by autophagy to provide material basis for energy synthesis and maintain cell homeostasis; on the other hand, over-activated autophagy can also increase cardiomyocyte death. Ischemic heart disease has a complex pathological mechanism, and the occurrence of autophagy is closely related to the survival or death of myocardial cells, so the regulation of autophagy may be an important therapeutic target for ischemic heart disease. Traditional Chinese medicine(TCM) with obvious effects, unique advantages and great potential has been widely used in the treatment of ischemic heart disease. In recent years, more and more studies have found that TCM can protect myocardium by regulating autophagy of cardiomyocytes. In this review, we summarized recent studies on the regulation of autophagy in myocardial cells by traditional Chinese medicine in ischemic heart disease. The pharmacological mechanism of Chinese medicinein regulating autophagy to protect cardiomyocytes was reviewed through different ways(promoting or inhibiting autophagy) from three levels, i.e. active ingredient, as well as drug pair and compound. The specific mechanism of Chinese medicine in regulating autophagy to protect ischemic heart disease was explored to provide references or new ideas for clinical treatment and drug development of ischemic heart disease.
- Open Access
- 14 May 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 26 (18) , 2247-2267
Computed tomography vs liver stiffness measurement and magnetic resonance imaging in evaluating esophageal varices in cirrhotic patients: A systematic review and meta-analysis
Computed tomography vs liver stiffness measurement and magnetic resonance imaging in evaluating esophageal varices in cirrhotic patients: A systematic review and meta-analysis
- 14 May 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 26 (18) , 2247-2267
Open AccessComputed tomography vs liver stiffness measurement and magnetic resonance imaging in evaluating esophageal varices in cirrhotic patients: A systematic review and meta-analysis
Computed tomography vs liver stiffness measurement and magnetic resonance imaging in evaluating esophageal varices in cirrhotic patients: A systematic review and meta-analysis
- Open Access
- 1 January 2020
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 93, 2-059
Modulistat, a PHD inhibitor, ameliorated erythropoiesis in adenine-induced nephropathy mice
Aim: Erythropoietin (EPO) is essential for the hematopoiesis. Kidney is the major organ to produce EPO in adults, so that kidney damage reduces its level in the body, resulting in anemia. Hypoxia-inducible factor is a well known translational factor to induce adaptive responses in the cell, and plays significant role on the EPO gene translation in the EPO producing cells. Therefore, the inhibitors of prolyl hydroxylase domain-containing protein (PHD) is awaited for one of the new therapeutic strategies against renal anemia. Likewise, it can be predictable that tons of patients who receive the PHD inhibitor have renal dysfunction as a cause of anemia, while the potential reno-protective effects of PHD inhibitor have not been evaluated well. In the present study, we investigated the effects of modulistat, a PHD inhibitor, on anemia and renal dysfunction when initiated after the onset of adenine-induced nephropathy.Methods: Male C57Bl/6J mice received adenine orally for the induction of nephropathy. After the onset of nephropathy, the mice were separated into 2 groups and received either vehicle or modulistat (3 mg/kg/day, p.o.) for 4 weeks.Results: There was no difference in hematocrit level between vehicle- and modulistat-treated groups (34.8±0.9 vs. 34.8±0.6%). At 4 weeks of the administration, vehicle-treated mice showed significant anemia (hematocrit level: 28.5±1.0%), and modulistat ameliorated the anemia (44.3±1.4%). Vehicle-treated mice exhibited reduction of creatinine clearance and body weight, increase in blood urea nitrogen, progressed histopathological changes, immune cells infiltration and dehydration. Modulistat improved immune cells infiltration and dehydration but not the other parameters. Conclusion: Modulistat treatment after the onset of nephropathy could recover mice from anemia. Modulistat improved some parameters of renal abnormality but unable to restore the renal function.
- 1 January 2020
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 93, 2-059
Open AccessModulistat, a PHD inhibitor, ameliorated erythropoiesis in adenine-induced nephropathy mice
Aim: Erythropoietin (EPO) is essential for the hematopoiesis. Kidney is the major organ to produce EPO in adults, so that kidney damage reduces its level in the body, resulting in anemia. Hypoxia-inducible factor is a well known translational factor to induce adaptive responses in the cell, and plays significant role on the EPO gene translation in the EPO producing cells. Therefore, the inhibitors of prolyl hydroxylase domain-containing protein (PHD) is awaited for one of the new therapeutic strategies against renal anemia. Likewise, it can be predictable that tons of patients who receive the PHD inhibitor have renal dysfunction as a cause of anemia, while the potential reno-protective effects of PHD inhibitor have not been evaluated well. In the present study, we investigated the effects of modulistat, a PHD inhibitor, on anemia and renal dysfunction when initiated after the onset of adenine-induced nephropathy.Methods: Male C57Bl/6J mice received adenine orally for the induction of nephropathy. After the onset of nephropathy, the mice were separated into 2 groups and received either vehicle or modulistat (3 mg/kg/day, p.o.) for 4 weeks.Results: There was no difference in hematocrit level between vehicle- and modulistat-treated groups (34.8±0.9 vs. 34.8±0.6%). At 4 weeks of the administration, vehicle-treated mice showed significant anemia (hematocrit level: 28.5±1.0%), and modulistat ameliorated the anemia (44.3±1.4%). Vehicle-treated mice exhibited reduction of creatinine clearance and body weight, increase in blood urea nitrogen, progressed histopathological changes, immune cells infiltration and dehydration. Modulistat improved immune cells infiltration and dehydration but not the other parameters. Conclusion: Modulistat treatment after the onset of nephropathy could recover mice from anemia. Modulistat improved some parameters of renal abnormality but unable to restore the renal function.